Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways.

Kornberg Z, Chou J, Feng FY, Ryan CJ.

Ann Transl Med. 2018 May;6(9):161. doi: 10.21037/atm.2018.05.06. Review.

2.

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.

Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A; PCF/SU2C International Prostate Cancer Dream Team, Robinson DR, Chinnaiyan AM.

Cell. 2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016/j.cell.2018.04.034.

PMID:
29906450
3.

EWS/ETS-driven Ewing Sarcoma requires BET bromodomain proteins.

Gollavilli PN, Pawar A, Wilder-Romans K, Ramakrishnan N, Engelke CG, Dommeti VL, Krishnamurthy PM, Nallasivam A, Apel IJ, Xu T, Qin Z, Feng FY, Asangani IA.

Cancer Res. 2018 Jun 13. pii: canres.0484.2018. doi: 10.1158/0008-5472.CAN-18-0484. [Epub ahead of print]

PMID:
29898995
4.

Rational design of an anchoring peptide for high-efficiency and quantitative modification of peptides and DNA strands on gold nanoparticles.

Li XY, Feng FY, Zhou XD, Hu JM.

Nanoscale. 2018 Jun 11. doi: 10.1039/c8nr03565b. [Epub ahead of print]

PMID:
29888777
5.

The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.

Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, Simko JP, Cowan JE, Lehrer J, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes M, Plessis MD, Buerki C, Tenggara I, Davicioni E, Carroll PR.

Eur Urol. 2018 May 28. pii: S0302-2838(18)30362-2. doi: 10.1016/j.eururo.2018.05.014. [Epub ahead of print]

PMID:
29853306
6.

Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.

Zhang Y, Pitchiaya S, Cieślik M, Niknafs YS, Tien JC, Hosono Y, Iyer MK, Yazdani S, Subramaniam S, Shukla SK, Jiang X, Wang L, Liu TY, Uhl M, Gawronski AR, Qiao Y, Xiao L, Dhanasekaran SM, Juckette KM, Kunju LP, Cao X, Patel U, Batish M, Shukla GC, Paulsen MT, Ljungman M, Jiang H, Mehra R, Backofen R, Sahinalp CS, Freier SM, Watt AT, Guo S, Wei JT, Feng FY, Malik R, Chinnaiyan AM.

Nat Genet. 2018 Jun;50(6):814-824. doi: 10.1038/s41588-018-0120-1. Epub 2018 May 28.

PMID:
29808028
7.

Development and validation of a prostate cancer genomic signature that predicts early ADT treatment response following radical prostatectomy.

Karnes RJ, Sharma V, Choeurng V, Al-Deen Ashab H, Erho NG, Alshalalfa M, Trock BJ, Ross AE, Yousefi K, Tsai HK, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM.

Clin Cancer Res. 2018 May 14. pii: clincanres.2745.2017. doi: 10.1158/1078-0432.CCR-17-2745. [Epub ahead of print]

PMID:
29760221
8.

PDXliver: a database of liver cancer patient derived xenograft mouse models.

He S, Hu B, Li C, Lin P, Tang WG, Sun YF, Feng FY, Guo W, Li J, Xu Y, Yao QL, Zhang X, Qiu SJ, Zhou J, Fan J, Li YX, Li H, Yang XR.

BMC Cancer. 2018 May 9;18(1):550. doi: 10.1186/s12885-018-4459-6.

9.

Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation.

Vasudevan HN, Braunstein SE, Phillips JJ, Pekmezci M, Tomlin BA, Wu A, Reis GF, Magill ST, Zhang J, Feng FY, Nicholaides T, Chang SM, Sneed PK, McDermott MW, Berger MS, Perry A, Raleigh DR.

Cell Rep. 2018 Mar 27;22(13):3672-3683. doi: 10.1016/j.celrep.2018.03.013.

10.

Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.

Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, Feng FY, Speers C, Overmoyer B, Sabel M, Schott AF, Pierce L; Translational Breast Cancer Research Consortium.

J Clin Oncol. 2018 May 1;36(13):1317-1322. doi: 10.1200/JCO.2017.77.2665. Epub 2018 Mar 20.

PMID:
29558281
11.

Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer.

Dess RT, Devasia TP, Aghdam N, Jackson WC, Soni PD, Smith CP, Mitchell AL, Suy S, Hamstra DA, Jolly S, Nguyen PL, Feng FY, Schipper MJ, Skolarus TA, Miller DC, Wittmann DA, Collins SP, Spratt DE.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):376-386. doi: 10.1016/j.ijrobp.2018.01.055. Epub 2018 Jan 31.

PMID:
29487023
12.

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF 3rd, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL.

Eur Urol. 2018 Feb 22. pii: S0302-2838(18)30098-8. doi: 10.1016/j.eururo.2018.01.043. [Epub ahead of print]

PMID:
29478736
13.

Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.

Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM.

Mol Cancer Res. 2018 Apr;16(4):643-654. doi: 10.1158/1541-7786.MCR-17-0539. Epub 2018 Feb 16.

PMID:
29453313
14.

Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival.

Jackson WC, Suresh K, Tumati V, Allen SG, Dess RT, Salami SS, George A, Kaffenberger SD, Miller DC, Hearn JWD, Jolly S, Mehra R, Hollenbeck BK, Palapattu GS, Schipper M, Feng FY, Morgan TM, Desai NB, Spratt DE.

Eur Urol. 2018 Jan 3. pii: S0302-2838(17)31070-9. doi: 10.1016/j.eururo.2017.12.023. [Epub ahead of print]

PMID:
29306514
15.

A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.

Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):40-47. doi: 10.1016/j.prro.2017.08.004. Epub 2017 Aug 16.

PMID:
29304991
16.

Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer.

Yang DD, Krasnova A, Nead KT, Choueiri TK, Hu JC, Hoffman KE, Yu JB, Spratt DE, Feng FY, Trinh QD, Nguyen PL.

Ann Oncol. 2018 Feb 1;29(2):386-391. doi: 10.1093/annonc/mdx744.

PMID:
29267861
17.

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM.

J Clin Oncol. 2018 Apr 1;36(10):991-999. doi: 10.1200/JCO.2017.75.7310. Epub 2017 Dec 20.

PMID:
29261439
18.

Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA.

Hosono Y, Niknafs YS, Prensner JR, Iyer MK, Dhanasekaran SM, Mehra R, Pitchiaya S, Tien J, Escara-Wilke J, Poliakov A, Chu SC, Saleh S, Sankar K, Su F, Guo S, Qiao Y, Freier SM, Bui HH, Cao X, Malik R, Johnson TM, Beer DG, Feng FY, Zhou W, Chinnaiyan AM.

Cell. 2017 Dec 14;171(7):1559-1572.e20. doi: 10.1016/j.cell.2017.11.040.

PMID:
29245011
19.

Travel distance and stereotactic body radiotherapy for localized prostate cancer.

Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF 3rd, Nguyen PL.

Cancer. 2018 Mar 15;124(6):1141-1149. doi: 10.1002/cncr.31190. Epub 2017 Dec 12.

PMID:
29231964
20.

Differential impact of RB status on E2F1 reprogramming in human cancer.

McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, De Laere B, Dirix L, Visakorpi T, Li F, Feng FY, de Bono J, Demichelis F, Rubin MA, Brown M, Knudsen KE.

J Clin Invest. 2018 Jan 2;128(1):341-358. doi: 10.1172/JCI93566. Epub 2017 Dec 4.

21.

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

J Clin Oncol. 2018 Feb 20;36(6):581-590. doi: 10.1200/JCO.2017.74.2940. Epub 2017 Nov 29.

PMID:
29185869
22.

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.

Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA.

Oncotarget. 2017 Sep 22;8(52):89848-89866. doi: 10.18632/oncotarget.21163. eCollection 2017 Oct 27.

24.

High stability of gold nanoparticles towards DNA modification and efficient hybridization via a surfactant-free peptide route.

Li XY, Feng FY, Wu ZT, Liu YZ, Zhou XD, Hu JM.

Chem Commun (Camb). 2017 Oct 31;53(87):11909-11912. doi: 10.1039/c7cc06827a.

PMID:
29044254
25.

Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference.

Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):274-284. doi: 10.1016/j.ijrobp.2017.05.044. Epub 2017 Jun 9.

PMID:
28964588
26.

LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.

Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, Karnes RJ, Chadwick D, van der Kwast T, Boutros PC, Arrowsmith CH, Feng FY, Joshua AM, Zoubeidi A, Cai C, He HH.

Cancer Res. 2017 Oct 15;77(20):5479-5490. doi: 10.1158/0008-5472.CAN-17-0496. Epub 2017 Sep 15.

PMID:
28916652
27.

TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.

Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L.

Clin Cancer Res. 2017 Nov 15;23(22):7072-7083. doi: 10.1158/1078-0432.CCR-17-0413. Epub 2017 Sep 12.

PMID:
28899973
28.

Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection.

Shen MY, Chen JF, Luo CH, Lee S, Li CH, Yang YL, Tsai YH, Ho BC, Bao LR, Lee TJ, Jan YJ, Zhu YZ, Cheng S, Feng FY, Chen P, Hou S, Agopian V, Hsiao YS, Tseng HR, Posadas EM, Yu HH.

Adv Healthc Mater. 2018 Feb;7(3). doi: 10.1002/adhm.201700701. Epub 2017 Sep 11.

PMID:
28892262
29.

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer.

Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng FY.

NPJ Breast Cancer. 2017 Aug 18;3:29. doi: 10.1038/s41523-017-0038-2. eCollection 2017.

30.

Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer.

Sinha S, Muralidhar V, Feng FY, Nguyen PL.

Prostate Int. 2017 Sep;5(3):89-94. doi: 10.1016/j.prnil.2017.04.003. Epub 2017 Apr 18.

31.

Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities.

Green M, Feng FY, Mehra R, Spratt DE.

Immunotherapy. 2017 Aug;9(9):695-699. doi: 10.2217/imt-2017-0059. Epub 2017 Aug 3. No abstract available.

32.

Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation.

Yin Y, Li R, Xu K, Ding S, Li J, Baek G, Ramanand SG, Ding S, Liu Z, Gao Y, Kanchwala MS, Li X, Hutchinson R, Liu X, Woldu SL, Xing C, Desai NB, Feng FY, Burma S, de Bono JS, Dehm SM, Mani RS, Chen BPC, Raj GV.

Cancer Res. 2017 Sep 15;77(18):4745-4754. doi: 10.1158/0008-5472.CAN-17-0164. Epub 2017 Jul 28.

PMID:
28754673
33.

Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF Rd, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL.

Eur Urol Focus. 2017 Jun 17. pii: S2405-4569(17)30148-7. doi: 10.1016/j.euf.2017.05.011. [Epub ahead of print]

PMID:
28753811
34.

Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes.

Spratt DE, Chen YW, Mahal BA, Osborne JR, Zhao SG, Morgan TM, Palapattu G, Feng FY, Nguyen PL.

Eur Urol Focus. 2016 Dec;2(5):532-539. doi: 10.1016/j.euf.2016.03.010. Epub 2016 Apr 1.

PMID:
28723519
35.

A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.

Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY.

Eur Urol. 2018 Feb;73(2):156-165. doi: 10.1016/j.eururo.2017.06.027. Epub 2017 Jul 14. Review.

PMID:
28716370
36.

Erectile function after stereotactic body radiotherapy for localized prostate cancer.

Dess RT, Hartman HE, Aghdam N, Jackson WC, Soni PD, Abugharib AE, Suy S, Desai NB, Zumsteg ZS, Mehra R, Morgan TM, Feng FY, Hamstra DA, Schipper MJ, Collins SP, Spratt DE.

BJU Int. 2018 Jan;121(1):61-68. doi: 10.1111/bju.13962. Epub 2017 Aug 17.

PMID:
28710895
37.

Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications.

Aggarwal RR, Feng FY, Small EJ.

Oncology (Williston Park). 2017 Jun 15;31(6):467-74. Review.

38.

Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.

Fei T, Chen Y, Xiao T, Li W, Cato L, Zhang P, Cotter MB, Bowden M, Lis RT, Zhao SG, Wu Q, Feng FY, Loda M, He HH, Liu XS, Brown M.

Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):E5207-E5215. doi: 10.1073/pnas.1617467114. Epub 2017 Jun 13.

39.

Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG.

Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049.

40.

Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer.

Dess RT, Morgan TM, Nguyen PL, Mehra R, Sandler HM, Feng FY, Spratt DE.

Curr Urol Rep. 2017 Jul;18(7):55. doi: 10.1007/s11934-017-0700-0. Review.

PMID:
28589403
41.

Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy.

Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL.

Urol Oncol. 2017 Sep;35(9):542.e25-542.e32. doi: 10.1016/j.urolonc.2017.04.018. Epub 2017 May 19.

PMID:
28533151
42.

Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.

Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, Spratt DE, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, Kolisnik T, Margrave J, Yousefi K, Choeurng V, Davicioni E, Trock BJ, Kane CJ, Pollack A, Davis JW, Feng FY, Klein EA.

Eur Urol. 2017 Nov;72(5):845-852. doi: 10.1016/j.eururo.2017.05.009. Epub 2017 May 19.

43.

External beam radiation therapy with or without low-dose-rate brachytherapy: Analysis of favorable and unfavorable intermediate-risk prostate cancer patients.

Abugharib AE, Dess RT, Soni PD, Narayana V, Evans C, Gaber MS, Feng FY, McLaughlin PW, Spratt DE.

Brachytherapy. 2017 Jul - Aug;16(4):782-789. doi: 10.1016/j.brachy.2017.04.001. Epub 2017 May 9.

PMID:
28499487
44.

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.

Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY.

JAMA Oncol. 2017 Dec 1;3(12):1663-1672. doi: 10.1001/jamaoncol.2017.0751.

45.

National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.

Yang DD, Muralidhar V, Mahal BA, Labe SA, Nezolosky MD, Vastola ME, King MT, Martin NE, Orio PF 3rd, Choueiri TK, Trinh QD, Spratt DE, Hoffman KE, Feng FY, Nguyen PL.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):338-343. doi: 10.1016/j.ijrobp.2017.02.020. Epub 2017 Feb 21.

PMID:
28463152
46.

Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.

Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL.

Ann Oncol. 2017 May 1;28(5):1098-1104. doi: 10.1093/annonc/mdx041.

PMID:
28453693
47.

Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.

Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY.

Cancer Discov. 2017 Sep;7(9):999-1005. doi: 10.1158/2159-8290.CD-17-0146. Epub 2017 Apr 27.

48.

Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.

Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LLC, du Plessis M, Choeurng V, Haddad Z, Buerki C, Davicioni E, Weinmann S, Freedland SJ, Klein EA, Karnes RJ, Feng FY.

J Clin Oncol. 2017 Jun 20;35(18):1991-1998. doi: 10.1200/JCO.2016.70.2811. Epub 2017 Mar 30. Review.

PMID:
28358655
49.

Pan-Cancer Analysis of Genomic Sequencing Among the Elderly.

Wahl DR, Nguyen PL, Santiago M, Yousefi K, Davicioni E, Shumway DA, Speers C, Mehra R, Feng FY, Osborne JR, Spratt DE.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):726-732. doi: 10.1016/j.ijrobp.2017.01.002. Epub 2017 Jan 7.

PMID:
28258894
50.

Down-regulation of RASA1 Is Associated with Poor Prognosis in Human Hepatocellular Carcinoma.

Chen YL, Huang WC, Yao HL, Chen PM, Lin PY, Feng FY, Chu PY.

Anticancer Res. 2017 Feb;37(2):781-785.

PMID:
28179330

Supplemental Content

Support Center